Dulaglutide
Also known as: Trulicity
Dulaglutide is a long-acting GLP-1 receptor agonist that mimics the incretin hormone GLP-1 to regulate blood glucose levels and promote weight loss. This once-weekly injectable medication works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying.
Dulaglutide is a 59.67 kDa research peptide. Dulaglutide is a long-acting GLP-1 receptor agonist that mimics the incretin hormone GLP-1 to regulate blood glucose levels and promote weight loss. This once-weekly injectable medication works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying.
Also called: Trulicity
59.67 kDa
Molecular Weight
Daltons
4
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
0.75-1.5
Typical Dose
mg
Overview
Dulaglutide represents a significant advancement in GLP-1 receptor agonist therapy, engineered for extended duration of action through its unique molecular structure. The compound consists of a GLP-1 analog linked to an immunoglobulin G4 (IgG4) Fc fragment, which extends its half-life to approximately 5 days and enables once-weekly dosing. Research demonstrates that dulaglutide activates GLP-1 receptors in pancreatic beta cells, intestinal L-cells, and hypothalamic neurons involved in appetite regulation. The medication's prolonged action results from reduced renal clearance and resistance to DPP-4 degradation. Clinical studies show dulaglutide produces sustained improvements in glycemic control while promoting significant weight reduction through central appetite suppression and delayed gastric emptying. The compound's molecular design allows for consistent plasma concentrations throughout the dosing interval, providing stable metabolic effects. Research applications focus on its potential for treating obesity, metabolic syndrome, and investigating the broader physiological roles of GLP-1 signaling pathways.
Key Takeaways: Dulaglutide
- Strongest evidence supports Dulaglutide for significant weight loss and improved glycemic control
- Research doses typically range from 0.75 to 1.5 mg via subcutaneous
- 4 benefits with strong evidence, 3 moderate, 0 preliminary
- Half-life: 5 days
- 4 cited research studies in this guide
Mechanism of Action
Dulaglutide functions as a selective GLP-1 receptor agonist that binds to and activates GLP-1 receptors throughout the body. Upon receptor binding, it stimulates adenylyl cyclase activity, increasing intracellular cyclic adenosine monophosphate (cAMP) levels. This cascade triggers glucose-dependent insulin secretion from pancreatic beta cells while simultaneously inhibiting glucagon release from alpha cells. The compound crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus, particularly in the arcuate nucleus, leading to enhanced satiety signaling and reduced food intake. Dulaglutide also slows gastric emptying by acting on receptors in the gastric antrum and duodenum, contributing to improved postprandial glucose control and prolonged satiety. The medication's extended half-life results from its fusion to an IgG4 Fc fragment, which prevents rapid kidney filtration and provides protection from proteolytic degradation.
Research Benefits
Dulaglutide at a Glance
Dulaglutide functions as a selective GLP-1 receptor agonist that binds to and activates GLP-1 receptors throughout the body.
Significant Weight Loss
Strong EvidenceClinical trials demonstrate dulaglutide produces dose-dependent weight reduction averaging 3-8% of baseline body weight over 26-52 weeks. The weight loss occurs through reduced caloric intake driven by enhanced satiety and delayed gastric emptying, with effects maintained throughout treatment duration.
Improved Glycemic Control
Strong EvidenceResearch shows dulaglutide reduces HbA1c levels by 0.7-1.5% compared to placebo, with glucose-dependent insulin secretion preventing hypoglycemic episodes. The compound maintains stable blood glucose levels throughout the weekly dosing interval.
Cardiovascular Risk Reduction
Strong EvidenceLarge-scale clinical trials demonstrate dulaglutide reduces major adverse cardiovascular events by 12% in patients with established cardiovascular disease. Benefits include reduced risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
Appetite Suppression
Strong EvidenceDulaglutide activates hypothalamic GLP-1 receptors to enhance satiety signaling and reduce food intake. Studies show significant reductions in daily caloric consumption and decreased cravings for high-calorie foods within 4-8 weeks of treatment initiation.
Beta Cell Preservation
Moderate EvidenceResearch indicates dulaglutide may help preserve pancreatic beta cell function through reduced glucotoxicity and direct cytoprotective effects. Animal studies suggest the compound promotes beta cell proliferation and prevents apoptosis.
Blood Pressure Reduction
Moderate EvidenceClinical studies report modest but consistent reductions in systolic blood pressure averaging 2-4 mmHg with dulaglutide treatment. The mechanism likely involves direct vasodilatory effects and weight loss-mediated improvements in vascular function.
Liver Fat Reduction
Moderate EvidenceImaging studies show dulaglutide reduces hepatic steatosis and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease. The effects appear related to weight loss and improved insulin sensitivity.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Weight management research | 0.75–1.5 mg | subcutaneous |
| Metabolic function studies | 1.5–3 mg | subcutaneous |
| Cardiovascular outcome research | 1.5–1.5 mg | subcutaneous |
Frequency
Once weekly
Timing
Same day each week, any time of day, with or without food
Cycle Length
Research protocols typically range from 12-52 weeks
Research Notes
- 1Injection site should be rotated between thigh, abdomen, and upper arm
- 2Allow pen to reach room temperature before injection
- 3Do not shake the pen - may cause protein aggregation
- 4Research dose escalation typically starts at 0.75mg weekly for 4 weeks
- 5Maximum researched dose is 3.0mg weekly in clinical trials
Reconstitution Guide
Standard Reconstitution
Vial Size
1.5 mg
Bacteriostatic Water
0.5 mL
Concentration
30 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Dulaglutide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 0.5 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 24 months unopened, 14 days after first use.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
24 months unopened, 14 days after first use
Important Notes
- •Pre-filled pens do not require reconstitution
- •Store in original carton to protect from light
- •Do not freeze or use if frozen
- •Allow to reach room temperature before injection
- •Discard pen 14 days after first use even if medication remains
Dulaglutide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Dulaglutide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea (most common, affects 15-30% of users)
- !Vomiting and diarrhea
- !Decreased appetite
- !Abdominal pain and discomfort
- !Injection site reactions (redness, swelling)
- !Fatigue and headache
- !Constipation
- !Hypoglycemia (when combined with other diabetes medications)
- !Pancreatitis (rare but serious)
- !Gallbladder disease including cholelithiasis
Potential Interactions
- ⚡Insulin and sulfonylureas (increased hypoglycemia risk)
- ⚡Oral medications (delayed absorption due to gastric emptying effects)
- ⚡Warfarin and other anticoagulants (monitor INR closely)
- ⚡Digoxin (potential for altered absorption)
- ⚡Acetaminophen (delayed peak concentration but similar total exposure)
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes (AWARD-5): a randomized, controlled trial
52-week trial showing dulaglutide 1.5mg provided superior glycemic control and weight loss compared to sitagliptin, with HbA1c reduction of 1.1% vs 0.4%.
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, randomized trial
Demonstrated dulaglutide's efficacy and safety in patients with moderate-to-severe chronic kidney disease, showing non-inferior glycemic control with significant weight reduction.
Effect of dulaglutide on cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized trial
Large cardiovascular outcomes trial showing 12% reduction in major adverse cardiovascular events with dulaglutide compared to placebo over median 5.4 years follow-up.
Efficacy of dulaglutide on glycemic control and weight in patients with type 2 diabetes: systematic review and meta-analysis
Meta-analysis of 23 randomized controlled trials confirming dulaglutide's efficacy for glycemic control and weight management, with dose-dependent effects observed.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Dulaglutide has a half-life of approximately 5 days, meaning it remains active in your system for about 3-4 weeks after the last injection. The extended half-life allows for once-weekly dosing while maintaining therapeutic effects throughout the dosing interval.
Clinical trials show average weight loss of 3-8% of baseline body weight over 6-12 months of treatment. Individual results vary, with some patients experiencing greater weight loss, particularly at higher doses. Weight loss typically begins within 4-8 weeks and continues throughout treatment.
Dulaglutide alone rarely causes hypoglycemia because it works in a glucose-dependent manner, only stimulating insulin when blood sugar is elevated. However, when combined with insulin or sulfonylureas, the risk of low blood sugar increases significantly and requires dose adjustments.
The most common side effects are gastrointestinal, including nausea (15-30%), vomiting, diarrhea, and decreased appetite. These effects are usually mild to moderate and tend to decrease over time. Injection site reactions and headache are also frequently reported.
Dulaglutide comes in a pre-filled pen that requires no mixing. Inject subcutaneously in the thigh, abdomen, or upper arm, rotating injection sites weekly. Allow the pen to reach room temperature before injection and never shake it, as this can damage the protein.
Dulaglutide offers the convenience of once-weekly dosing compared to daily GLP-1 agonists. Clinical trials show similar efficacy to other GLP-1 agonists for glycemic control, with comparable weight loss effects. The choice often depends on dosing preference, side effect profile, and individual response.
Dulaglutide can be used in patients with mild to moderate kidney impairment without dose adjustment. Clinical trials specifically studied patients with chronic kidney disease and found the medication to be safe and effective, though close monitoring is recommended.
Dulaglutide begins affecting blood sugar within hours of injection, with peak effects occurring 24-72 hours after administration. Weight loss effects typically become noticeable within 4-8 weeks, while maximum glycemic benefits develop over 8-12 weeks of consistent use.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.